Metal and Inflammatory Targets for Alzheimers Disease
The DOI matches its Crossref record.
Abstract
Alzheimer's disease (AD) has become linked to inflammation and metal biology. Metals (copper, zinc and iron) and inflammatory cytokines are significant factors that increase the onset of sporadic late onset forms of the dementia. The genetic discovery that alleles in the hemochromatosis gene accelerate the onset of disease by five years has certainly validated interest in the metallobiology of AD as originally described by biochemical criteria. Also the presence of an Iron-Responsive Element (IRE) in the 5'UTR of the Amyloid Precursor Protein transcript (APP 5'UTR) provided the first molecular biological support for the current model that APP of AD is a metaloprotein. At the biochemical level, copper, zinc and iron were shown to accelerate the aggregation of the Abeta peptide and enhance metal catalyzed oxidative stress associated with amyloid plaque formation. These amyloid associated events remain the central pathological hallmark of AD in the brain cortex region of AD patients. The involvement of metals in the plaque of AD patients and the demonstration of metal dependent translation of APP mRNA have encouraged the development of chelators as a major new therapeutic strategy for the treatment of AD, running parallel to the development of a vaccine. The other notable pathological feature of AD discussed here is inflammation. The presence of neuro-inflammatory events during AD was supported by clinical trials wherein use of non steroidal anti-inflammatory drugs (NSAIDs) was shown to reduce the risk of developing AD. Drug targets that address inflammation include the use of small molecules that prevent Abeta peptide from activating microglia, the use of cytokine suppressive anti-inflammatory drugs (CSAIDS), and the continued search for a vaccine directed to Abeta sub-fragments (even though the full-length Abeta immunogen generated brain-inflammation and encephalitis in some patients). Our laboratory currently uses a transfection-based assay to screen for small molecule drugs that selectively suppress the capacity of the APP 5'UTR to confer expression to a downstream reporter gene. Based on the presence of both an Interleukin-1 (IL-1) responsive acute box domain and an IRE in the APP 5'UTR, we predict that our APP 5'UTR directed drug screens will identify both novel metal chelators and novel NSAIDS. These lead drugs are readily testable to measure APP holoprotein expression in a cell based secondary assay, and by use of an APP transgenic mouse model to test potential beneficial effects of lead drug treatments on amyloid burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Iron, brain ageing and neurodegenerative disorders
Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1537 · Cited by 1,801
Mitochondrial abnormalities in Alzheimer brain: Mechanistic implications
Bubber, P., Haroutunian, V., Fisch, G., Blass, J. P., & Gibson, G. E. (2005) · Annals of Neurology · doi:10.1002/ana.20474 · Cited by 622
Anti-Inflammatory Drugs in the 21st Century
Rainsford, K. D. (2007) · Subcellular Biochemistry · doi:10.1007/1-4020-5688-5_1 · Cited by 463
Mandel, S., Amit, T., Reznichenko, L., Weinreb, O., & Youdim, M. B. H. (2006) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200500156 · Cited by 291
Oxidative stress and β-amyloid protein in Alzheimer’s disease
Cai, Z., Zhao, B., & Ratka, A. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-011-8155-9 · Cited by 279
Microglia and Alzheimer’s Disease
Merighi, S., Nigro, M., Travagli, A., & Gessi, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112990 · Cited by 236
Reznichenko, L., Amit, T., Zheng, H., Avramovich‐Tirosh, Y., Youdim, M. B. H., Weinreb, O., & Mandel, S. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03770.x · Cited by 189
“The limited number of neuroprotective studies carried out so far indicate that iron chelation therapy could be a viable neuroprotective approach for neurodegenerative disorders (Rogers and Lahiri 2004; Zecca et al. 2004; Youdim and Buccafusco 2005).”
BackgroundAshok, A., Rai, N. K., Tripathi, S., & Bandyopadhyay, S. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfu208 · Cited by 177
Mandel, S., Amit, T., Bar-Am, O., & Youdim, M. B. H. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.06.001 · Cited by 164
Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives
Mandel, S., Weinreb, O., Amit, T., & Youdim, M. B. H. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.12.027 · Cited by 157
Long, J. M., Maloney, B., Rogers, J. T., & Lahiri, D. K. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0266-3 · Cited by 141
Self-citationAvramovich‐Tirosh, Y., Amit, T., Bar‐Am, O., Zheng, H., Fridkin, M., & Youdim, M. B. H. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04258.x · Cited by 130
Amit, T., Avramovich‐Tirosh, Y., Youdim, M. B. H., & Mandel, S. (2008) · The FASEB Journal · doi:10.1096/fj.07-8627rev · Cited by 126
Ghribi, O., Golovko, M. Y., Larsen, B., Schrag, M., & Murphy, E. J. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04079.x · Cited by 97
RetractedA review of β-amyloid neuroimaging in Alzheimer's disease
Adlard, P. A., Tran, B. A., Finkelstein, D. I., Desmond, P. M., Johnston, L. A., Bush, A. I., & Egan, G. F. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00327 · Cited by 93
“Furthermore, APP mRNA is upregulated by IL-1, an inflammation cytokine, further promoting amyloidosis and reinforcing a self-perpetuating cycle (Rogers and Lahiri, 2004).”
BackgroundPeripheral Chemo-Cytokine Profiles in Alzheimers and Parkinsons Diseases
Reale, M., Greig, N., & Kamal, M. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709789055199 · Cited by 82
Targeting Metal Homeostasis as a Therapeutic Strategy for Alzheimer’s Disease
Department of Biomedical, M. A. N. S., Vilella, A., Daini, E., Department of Biomedical, M. A. N. S., De Benedictis, C. A., Cellular Neurobiology and Neuro-Nanotechnology Lab, D. O. B. S., Grabrucker, A. M., Cellular Neurobiology and Neuro-Nanotechnology Lab, D. O. B. S., Bernal Institute, U. O. L., & Health Research Institute (HRI), U. O. L. (2020) · Alzheimer’s Disease: Drug Discovery · doi:10.36255/exonpublications.alzheimersdisease.2020.ch5 · Cited by 12
“Like tetrathiomolybdate (TM) (a Cu chelator) and dimercaptopropanol (a Pb and Hg chelator), DFO reduces Aβ secretion and restrains the expression of APP holo-protein in vitro (84, 86).”
Background
Metadata
- Authors
- Rogers, J., & Lahiri, D.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2004-08-01
- Volume
- 5
- Issue
- 6
- Pages
- 535-551
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W2093499884
- Cited by
- 149
- References
- 0
- FWCI
- 7.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.